HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.
Bottom Line: In pregnant mice, PI-based cART but not dual-NRTI therapy was associated with significantly lower progesterone levels that directly correlated with fetal weight.Progesterone supplementation resulted in a significant improvement in fetal weight.In HIV-infected women, progesterone levels correlated significantly with birth weight percentile.
Affiliation: Toronto General Research Institute, University Health Network.Show MeSH
Related in: MedlinePlus
Mentions: To investigate whether decreases in progesterone levels directly contributed to reduced fetal weight, we supplemented PI-cART with 0.5 mg progesterone every 4 days, beginning on GD1. We observed a significant increase in fetal weight at GD15 in mice that received PI-cART supplemented with progesterone (Figure 3B), although fetal weight did not recover to the same levels as in the control. There was also a trend toward higher placental weight in the progesterone-supplemented group (Figure 3C). However, the number of resorptions was unaffected by the supplementation (Figure 3A), suggesting that cART must exert additional progesterone-independent effects during pregnancy that require further investigation. Progesterone administration did not significantly alter the birth outcomes of control mice (Supplementary Materials).Figure 3.
Affiliation: Toronto General Research Institute, University Health Network.